Search Results - "Heger, James J."

Hemorrhagic complications of thrombolytic therapy by Lauer, J E, Heger, J J, Mirro, M J

“…Thrombolytic therapy salvages ischemic myocardium by rapidly reestablishing coronary artery patency in acute myocardial infarction. One of its major…”
Get more information

Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide by Windle, J, Prystowsky, E N, Miles, W M, Heger, J J

“…The effects of amiodarone on the pharmacokinetic and electrophysiologic properties of procainamide were examined in eight patients treated for recurrent…”
Get more information

Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine by Stanton, Marshall S., Tuli, Mahmoud M., Radtke, Nancy L., Heger, James J., Miles, William M., Mock, Bruce H., Burt, Robert W., Wellman, Henry N., Zipes, Douglas P.

“…Transmural myocardial infarction in dogs produces denervation of sympathetic nerves in viable myocardium apical to the infarct that may be arrhythmogenic. It…”
Get full text

Arrhythmogenic effects of antiarrhythmic drugs: A study of 506 patients treated for ventricular tachycardia or fibrillation by Stanton, Marshall S., Prystowsky, Eric N., Fineberg, Naomi S., Miles, William M., Zipes, Douglas P., Heger, James J.

“…Antiarrhythmic therapy in 506 consecutive patients undergoing 1,268 antiarrhythmic drug trials for ventricular tachycardia or ventricular fibrillation was…”
Get full text

Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy by Minardo, J D, Heger, J J, Miles, W M, Zipes, D P, Prystowsky, E N

“…We retrospectively studied 28 patients with 38 episodes of newly occurring ventricular fibrillation during antiarrhythmic drug therapy. Twenty-six of these…”
Get more information

Amiodarone: Electrophysiologic actions, pharmacokinetics and clinical effects by Zipes, Douglas P., Prystowsky, Eric N., Heger, James J.

“…Interest in amiodarone has increased because of its remarkable efficacy as an antiarrhythmic agent. The purpose of this report is to review what is known about…”
Get full text

Relationships between amiodarone dosage, drug concentrations, and adverse side effects by Heger, J J, Prystowsky, E N, Zipes, D P

“…The relationships between size of loading dose and drug concentration, size of maintenance dose and drug concentration, and pulmonary and cutaneous adverse…”
Get more information

Role of electrophysiologic testing in managing patients who have ventricular tachycardia unrelated to coronary artery disease by Naccarelli, Gerald V., Prystowsky, Eric N., Jackman, Warren M., Heger, James J., Rahilly, G.Thomas, Zipes, Douglas P.

“…This study examined the usefulness of programmed electrical stimulation in managing 83 patients who had ventricular tachycardia not due to coronary artery…”
Get full text

Early experience with an implantable cardioverter by Zipes, D P, Heger, J J, Miles, W M, Mahomed, Y, Brown, J W, Spielman, S R, Prystowsky, E N

“…We tested the efficacy and safety of a fully programmable cardioverter weighing 95 g, in terminating sustained ventricular tachycardia. The device was…”
Get more information

Influence of tachycardia cycle length and antiarrhythmic drugs on pacing termination and acceleration of ventricular tachycardia by Naccarelli, G V, Zipes, D P, Rahilly, G T, Heger, J J, Prystowsky, E N

“…We examined the influence of ventricular tachycardia (VT) cycle length and antiarrhythmic drugs on the frequency of VT termination and acceleration by single…”
Get more information

Amiodarone: Risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study by Naccarelli, Gerald V., Fineberg, Naomi S., Zipes, Douglas P., Heger, James J., Duncan, Georgia, Prystowsky, Eric N.

“…Ventricular tachycardia induced by programmed electrical stimulation during amiodarone therapy often does not preclude a good clinical response. The purpose of…”
Get full text

Clinical transvenous cardioversion of recurrent life-threatening ventricular tachyarrhythmias: low energy synchronized cardioversion of ventricular tachycardia and termination of ventricular fibrillation in patients using a catheter electrode by Zipes, D P, Jackman, W M, Heger, J J, Chilson, D A, Browne, K F, Naccarelli, G V, Rahilly, Jr, G T, Prystowsky, E N

“…The purpose of this study was to test the efficacy, safety, and patient tolerance of transvenous cardioversion and defibrillation in patients who had recurrent…”
Get more information

Enhanced parasympathetic tone shortens atrial refractoriness in man by Prystowsky, Eric N., Naccarelli, Gerald V., Jackman, Warren M., Rinkenberger, Robert L., Heger, James J., Zipes, Douglas P.

“…The purpose of this study was to determine the effects of enhanced vagal tone on human right atrial refractoriness in 12 patients. A specially built neck…”
Get full text

Cibenzoline plasma concentration and antiarrhythmic effect by Brazzell, R K, Aogaichi, K, Heger, Jr, J J, Somberg, J C, Carliner, N H, Morganroth, J

“…The relationship between plasma concentrations of cibenzoline and its antiarrhythmic effect was evaluated in patients receiving the drug orally as part of an…”
Get more information

Clinical use and pharmacology of amiodarone by Heger, J J, Prystowsky, E N, Miles, W M, Zipes, D P

“…Amiodarone, an investigational drug in the United States, has had considerable use in this country and worldwide in the treatment of cardiac arrhythmias. This…”
Get more information

Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug by Browne, K F, Prystowsky, E N, Heger, J J, Cerimele, B J, Fineberg, N, Zipes, D P

“…Sudden death has occurred in monkeys fed large doses of probucol, a cholesterol-lowering drug, given in combination with an atherogenic diet. These monkeys…”
Get more information

Amiodarone Phenocopy of Fabry's Keratopathy by Whitley, Chester B, Tsai, Michael Y, Heger, James J, Prystowsky, Eric N, Zipes, Douglas P

“…To the Editor.—Recognition of the distinctive corneal opacity associated with amiodarone therapy has stimulated our interest in this drug-induced phenocopy of…”
Get full text

Clinical features of amiodarone-induced pulmonary toxicity by DUSMAN, R. E, STANTON, M. S, MILES, W. M, KLEIN, L. S, ZIPES, D. P, FINEBERG, N. S, HEGER, J. J

“…The incidence and clinical predictors of amiodarone pulmonary toxicity were examined in 573 patients treated with amiodarone for recurrent ventricular (456…”
Get full text

Five-year follow-up of 589 patients treated with amiodarone by Weinberg, B A, Miles, W M, Klein, L S, Bolander, J E, Dusman, R E, Stanton, M S, Heger, J J, Langefeld, C, Zipes, D P

“…Between 1977 and 1986, 589 patients (age, 57 +/- 13 years; 464 men and 125 women) received amiodarone for ventricular fibrillation (VF; 147 patients),…”
Get more information

Influence of the autonomic nervous system on the Q-T interval in man by Browne, Kevin F., Zipes, Douglas P., Heger, James J., Prystowsky, Eric N.

“…Drugs that affect the autonomic nervous system can influence the Q-T interval directly or by changing the heart rate. Bazett's formula to correct for rate may…”
Get full text